P53 and Ki‐67 Immunoreactivity in Human Prostate Cancer and Benign Hyperplasia

British Journal of Urology

Volumn 69, Issue 6, 1992, Pages 609-613

  THOMPSON, S J ^a   MELLON, K ^a   CHARLTON, R G ^a   MARSH, C ^a   ROBINSON, MARY ^a   NEAL, D E ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ARTICLE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

AGED; HUMAN; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NUCLEAR PROTEINS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN P53;

EID: 0026690458     PISSN: 00071331     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.1992.tb15632.x     Document Type: Article

References (40)

1. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
2. Genetic and immunochemical analysis of mutant p53 in human breast cancer
3. Ki‐67 immunostaining in primary breast cancer: pathological and clinical associations
4. Mouse p53 inhibits SV40 origin‐dependent DNA replication
5. p53 expression in breast cancer
6. The p53 proto‐oncogene can act as a suppressor of transformation
7. Prostate cancer grading: the NPCP system
8. Monoclonal antibody Ki‐67 defined growth fraction in benign hyperplasia and prostatic cancer
9. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form
10. p53 and DNA polymerasea compete for binding to SV40 T antigen
11. Cell cycle analysis of a cell proliferation‐associated human nuclear defined by the monoclonal antibody Ki‐67
12. Prognostic relevance of tumour‐cell growth fraction in malignant Non‐Hodgkin's Lymphomas
13. The early stages of absorption of injected horseradish in the proximal tubule of the mouse kidney. Ultrastructural cytochemistry by a new technique
14. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and its transformation
15. Increased expression of mutant forms of p53 oncogene in primary lung cancer
16. The p53 oncogene
17. Oligomerisation of oncoprotein p53
18. T antigen is bound to a host protein in SV40 transformed cells
19. High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene
20. Allele loss on short arm of chromosome 17 in breast cancer
21. Cell cycling in bladder carcinoma determined by monoclonal antibody Ki‐67
22. p53, c‐erbB‐2 and the epidermal growth factor receptor in the benign and malignant prostate
23. Wild type human p53 is antiproliferative in SV40‐transformed hamster cells
24. Human p53 gene is localised to short arm of chromosome 17
25. The epidermal growth factor receptor and the prognosis of bladder cancer
26. Immunocytochemical demonstration of S phase cells by anti‐bromodeoxy‐uridine monoclonal antibody in human prostate adenocarcinoma
27. S‐phase fraction of human prostate adenocarcinoma studied in vivo bromodeoxyuridine labelling
28. Mutations in the p53 gene occur in diverse tumour types
29. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
30. Growth fractions in human prostate carcinoma determined by Ki‐67 immunostaining
31. p53 mutations in colorectal cancer
32. p53: a frequent target for genetic abnormalities in lung cancer
33. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer
34. Allelic loss of chromosomes 9, 11, and 17 in human bladder cancer
35. Expression of the nuclear oncogene p53 in colon tumours
36. Genetic alterations during colorectal tumor development
37. Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes‐infected cells
38. Expression of mutant p53, c‐erbB‐2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder
39. Loss of heterozygosity on chromosomes 3, 13, and 17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung